Wednesday, September 22, 2021

Yearly Archives: 2007

Boston Life Sciences bids $35M for spinal cord drug license

Hopkinton-based Boston Life Sciences Inc. reports it has put up a potential $35 million-plus for an exclusive, worldwide license with BioAxone Therapeutic Inc. of...

Boston Life Sciences Acquires Rights to Develop and Commercialize Promising Phase II Spinal Cord...

Interim Results Report Drug's Safety and Possible Recovery of Function After Debilitating Injury; FDA "Orphan Drug" Status Provides Important Strategic Advantages HOPKINTON, Mass., Jan....

BioAxone Therapeutic Licenses Phase II Spinal Cord Injury Drug Cethrin(R) to Boston Life Sciences

MONTREAL, Jan. 4 /PRNewswire/ - BioAxone Therapeutic announced today that it has licensed its clinical phase II spinal cord injury drug Cethrin to Boston...

Levitra® Demonstrates Normal Function in 53% of Men with Spinal Cord Injury

Levitra® (vardenafil HCl) Demonstrates Normal Erectile Function in 53% of Men with Spinal Cord Injury (SCI) Changes to the European label for Levitra shows that...

Uric acid and spinal cord injury treatment

A novel approach from Rutgers holds potential for Central Nervous System damage NEW BRUNSWICK/PISCATAWAY, N.J. -- Uric acid is commonly associated with the excruciatingly painful...

Teresa Hukari makes painstaking progress

The year 2006 was a life-altering one for Teresa Hukari, a Hood River native who was injured last March in a freak skiing accident...

Steady progress for quadriplegic Wyoming man

Progress for Andy Scott comes in bits and pieces. The Powell, Wyo., man underwent experimental stem cell surgery in Europe six months ago in hopes...